HUP0401587A2 - Új elnyújtott kibocsátású orális adagolási forma - Google Patents

Új elnyújtott kibocsátású orális adagolási forma

Info

Publication number
HUP0401587A2
HUP0401587A2 HU0401587A HUP0401587A HUP0401587A2 HU P0401587 A2 HUP0401587 A2 HU P0401587A2 HU 0401587 A HU0401587 A HU 0401587A HU P0401587 A HUP0401587 A HU P0401587A HU P0401587 A2 HUP0401587 A2 HU P0401587A2
Authority
HU
Hungary
Prior art keywords
dosage form
oral dosage
release oral
active ingredient
extended
Prior art date
Application number
HU0401587A
Other languages
English (en)
Inventor
Karin Ellström
Ulf Kjellberg
Hakan Nyqvist
Annika Schweighofer
Maritta Temsamani
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0401587A2 publication Critical patent/HUP0401587A2/hu
Publication of HUP0401587A3 publication Critical patent/HUP0401587A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya az (R)-3-(N,N-diciklobutil-amino)-8-fluor-3,4-dihidro-2H-l-benzopirán-5-karboxamid hatóanyagot szabad bázis,gyógyszerészetileg elfogadható sói és/vagy hidrátjai vagy szolvátjaiformájában, adott esetben kötőanyagokkal, síkosító szerekkel, akibocsátást módosító ágensekkel és egyéb segédanyagokkal együtttartalmazó elnyújtott kibocsátású orális adagolási forma. A találmányszerinti új, elnyújtott kibocsátású orális adagolási forma a hatóanyagolyan vérplazmabeli koncentrációját eredményezi, amelynél nemkövetkezik be a hatóanyag gyors kezdeti emelkedése; maximáliskoncentrációjának eléréséhez szükséges idő legalább ötször olyanhosszú, mintha az illető hatóanyagot orálisan, vizes oldata alakjábanalkalmaznák; tartózkodási ideje pedig legalább háromszor olyan hosszú,mintha orálisan, vizes oldata alakjában alkalmaznák. A találmánytárgyát képezi továbbá az adagolási forma előállítására szolgálóeljárás, és az adagolási forma alkalmazása, elsősorban a központiidegrendszer zavarainak megelőzésére és/vagy kezelésére. Ó
HU0401587A 2001-08-29 2002-08-28 A new extended release oral dosage form HUP0401587A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102886A SE0102886D0 (sv) 2001-08-29 2001-08-29 New formulation
PCT/SE2002/001540 WO2003017982A1 (en) 2001-08-29 2002-08-28 A new extended release oral dosage form

Publications (2)

Publication Number Publication Date
HUP0401587A2 true HUP0401587A2 (hu) 2004-11-29
HUP0401587A3 HUP0401587A3 (en) 2007-03-28

Family

ID=20285177

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401587A HUP0401587A3 (en) 2001-08-29 2002-08-28 A new extended release oral dosage form

Country Status (15)

Country Link
US (1) US20040204482A1 (hu)
EP (1) EP1423098A1 (hu)
JP (1) JP2005504051A (hu)
KR (1) KR20040032976A (hu)
CN (1) CN1547466A (hu)
BR (1) BR0212166A (hu)
CA (1) CA2457339A1 (hu)
HU (1) HUP0401587A3 (hu)
IL (1) IL160372A0 (hu)
MX (1) MXPA04001812A (hu)
NO (1) NO20040866L (hu)
NZ (1) NZ531437A (hu)
SE (1) SE0102886D0 (hu)
WO (1) WO2003017982A1 (hu)
ZA (1) ZA200401085B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302824D0 (sv) * 2003-10-24 2003-10-24 Astrazeneca Ab New use
EP2603240B1 (en) * 2010-08-09 2019-11-20 Degama Smart Ltd. Probiotic liquid food products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
AR035642A1 (es) * 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor

Also Published As

Publication number Publication date
HUP0401587A3 (en) 2007-03-28
BR0212166A (pt) 2004-07-13
IL160372A0 (en) 2004-07-25
CN1547466A (zh) 2004-11-17
CA2457339A1 (en) 2003-03-06
ZA200401085B (en) 2005-06-22
WO2003017982A1 (en) 2003-03-06
US20040204482A1 (en) 2004-10-14
SE0102886D0 (sv) 2001-08-29
KR20040032976A (ko) 2004-04-17
NZ531437A (en) 2005-12-23
NO20040866L (no) 2004-04-19
MXPA04001812A (es) 2004-07-08
EP1423098A1 (en) 2004-06-02
JP2005504051A (ja) 2005-02-10

Similar Documents

Publication Publication Date Title
NO20052739L (no) CCR5-antagonister som medikamenter
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
HUP0004300A2 (hu) (S)-N-Etil-3-[1-(dimetil-amino)-etil]-N-metil-fenil-karbamátot és antioxidánst tartalmazó gyógyszerkészítmény
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301305A2 (hu) Dopamin D2/D3 receptor agonisták alkalmazása fibromialgia kezelésére szánt gyógyászati készítmények előállítására
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
HUP0402304A2 (hu) Deutériummal helyettesített dihidrofuranonszármazékok és azokat tartalmazó gyógyszerkészítmények
SE0102440D0 (sv) New compound
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
HUP0402358A2 (hu) Szelektív dopamin D4 receptor agonisták alkalmazása szexuális diszfunkciók kezelésére alkalmas gyógyszerkészítmény előállítására
SE0102887D0 (sv) New formulation
HUP0401587A2 (hu) Új elnyújtott kibocsátású orális adagolási forma
HUP0401798A2 (hu) Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására
NO20032006D0 (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees